A detailed history of Perceptive Advisors LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Perceptive Advisors LLC holds 2,979,235 shares of NUVL stock, worth $272 Million. This represents 7.96% of its overall portfolio holdings.

Number of Shares
2,979,235
Previous 2,549,077 16.88%
Holding current value
$272 Million
Previous $193 Million 57.61%
% of portfolio
7.96%
Previous 5.59%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$67.44 - $112.17 $29 Million - $48.3 Million
430,158 Added 16.88%
2,979,235 $305 Million
Q2 2024

Aug 14, 2024

SELL
$62.76 - $81.61 $14.7 Million - $19.1 Million
-234,377 Reduced 8.42%
2,549,077 $193 Million
Q1 2024

May 15, 2024

SELL
$72.35 - $88.99 $9.73 Million - $12 Million
-134,537 Reduced 4.61%
2,783,454 $209 Million
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $19.3 Million - $36.5 Million
454,540 Added 18.45%
2,917,991 $215 Million
Q3 2023

Nov 14, 2023

BUY
$39.12 - $49.85 $10.5 Million - $13.4 Million
268,630 Added 12.24%
2,463,451 $113 Million
Q2 2023

Aug 14, 2023

SELL
$23.58 - $44.68 $2.48 Million - $4.7 Million
-105,227 Reduced 4.57%
2,194,821 $92.6 Million
Q1 2023

May 15, 2023

BUY
$25.42 - $33.52 $1.14 Million - $1.51 Million
45,041 Added 2.0%
2,300,048 $60 Million
Q4 2022

Feb 14, 2023

BUY
$18.46 - $36.37 $11.1 Million - $21.8 Million
600,000 Added 36.25%
2,255,007 $67.2 Million
Q2 2022

Aug 15, 2022

SELL
$7.4 - $15.07 $714,795 - $1.46 Million
-96,594 Reduced 5.51%
1,655,007 $22.4 Million
Q1 2022

May 16, 2022

BUY
$11.65 - $19.57 $11.7 Million - $19.6 Million
1,001,601 Added 133.55%
1,751,601 $24.3 Million
Q3 2021

Nov 15, 2021

BUY
$18.25 - $38.35 $13.7 Million - $28.8 Million
750,000 New
750,000 $16.9 Million

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.92B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.